CITIGROUP INC - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
CITIGROUP INC ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$4,669,438
-22.9%
130,980
-0.2%
0.00%0.0%
Q2 2023$6,055,346
-43.2%
131,267
-50.6%
0.00%
-50.0%
Q1 2023$10,659,983
-7.6%
265,835
+6.8%
0.01%
-11.1%
Q4 2022$11,532,696
+108.8%
248,925
+86.6%
0.01%
+125.0%
Q3 2022$5,524,000
+9.6%
133,384
+57.9%
0.00%0.0%
Q2 2022$5,039,000
+196.8%
84,466
+261.2%
0.00%
+300.0%
Q1 2022$1,698,000
-65.7%
23,383
-60.3%
0.00%
-66.7%
Q4 2021$4,957,000
+84.8%
58,948
+98.2%
0.00%
+50.0%
Q3 2021$2,683,000
-49.0%
29,749
-46.1%
0.00%
-33.3%
Q2 2021$5,259,000
-3.8%
55,165
+14.9%
0.00%
-25.0%
Q1 2021$5,469,000
-5.9%
48,028
+14.4%
0.00%
+33.3%
Q4 2020$5,810,000
+1071.4%
41,967
+594.8%
0.00%
Q3 2020$496,000
-83.0%
6,040
-83.8%
0.00%
-100.0%
Q2 2020$2,923,000
+16.2%
37,374
-34.0%
0.00%0.0%
Q1 2020$2,516,000
+76.1%
56,642
+69.4%
0.00%
+100.0%
Q4 2019$1,429,000
-51.2%
33,441
-51.2%
0.00%
-50.0%
Q3 2019$2,930,000
+12.1%
68,500
+66.5%
0.00%0.0%
Q2 2019$2,613,000
-1.6%
41,135
+7.5%
0.00%
-33.3%
Q1 2019$2,656,000
-52.5%
38,277
-70.2%
0.00%
-50.0%
Q4 2018$5,587,000
-41.5%
128,481
+2.7%
0.01%
-25.0%
Q3 2018$9,552,000
+737.2%
125,111
+741.8%
0.01%
+700.0%
Q2 2018$1,141,000
-43.8%
14,862
-62.7%
0.00%
-50.0%
Q1 2018$2,032,000
-9.1%
39,879
-17.3%
0.00%0.0%
Q4 2017$2,236,000
+48.8%
48,219
+70.9%
0.00%
+100.0%
Q3 2017$1,503,000
-42.1%
28,216
-32.5%
0.00%
-50.0%
Q2 2017$2,594,000
-15.5%
41,774
-7.8%
0.00%
-33.3%
Q1 2017$3,069,000
-70.2%
45,296
-69.1%
0.00%
-66.7%
Q4 2016$10,310,000
+850.2%
146,644
+859.1%
0.01%
+800.0%
Q3 2016$1,085,000
+148.3%
15,290
+71.1%
0.00%
Q2 2016$437,000
-81.3%
8,935
-75.8%
0.00%
-100.0%
Q1 2016$2,335,000
+68.8%
36,885
+199.1%
0.00%
+200.0%
Q4 2015$1,383,000
+561.7%
12,331
+468.8%
0.00%
Q3 2015$209,000
-30.6%
2,168
-26.5%
0.00%
Q2 2015$301,000
-40.5%
2,948
-63.8%
0.00%
Q1 2015$506,000
+25.6%
8,151
-11.2%
0.00%
Q4 2014$403,000
+722.4%
9,176
+954.7%
0.00%
Q3 2014$49,000
+250.0%
870
+167.7%
0.00%
Q2 2014$14,000
+1300.0%
325
+1254.2%
0.00%
Q1 2014$1,000240.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders